Threshold analysis referring to base-case ranking
| Value | Change in ranking | |
| Decrease in TST-positive contacts % | ≤26 | TST-based strategy less expensive than QFT-G-based strategy |
| Reduction in cost of QFT-G EUR | ||
| Base-case assumption | ≤27.20 | QFT-G-based strategy least expensive |
| Lowest cost of RT 23# | ≤17.5 | QFT-G-based strategy least expensive |
| Increase in BCG vaccinees % | ≥88 | TST/BCG/QFT-G-based strategy least expensive |
| Decrease in BCG vaccinees % | ≤66 | QFT-G-based strategy less expensive than TST/BCG/QFT-G-based strategy |
| Increase in cost of QFT-G EUR | ||
| Base-case assumption | ≥73.8 | TST-based strategy less expensive than QFT-G-based strategy |
| Lowest cost of RT 23# | ≥67.8 | TST-based strategy less expensive than QFT-G-based strategy |
TST: tuberculin skin test; QFT-G: QuantiFERON-TB Gold; EUR: Euro; RT 23: purified protein derivative of tuberculin RT 23 (2 TU·0.1 mL-1) from the Danish Statens Serum Institute; BCG: bacille Calmette–Guérin. #: 1.5 EUR·dose-1.